Evidence map›Paper›PMID 33502678›Full record

ArticleJournal of neuro-oncology2021

Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography.

Sied Kebir, Laurèl Rauschenbach, Manuel Weber, Lazaros Lazaridis, Teresa Schmidt, Kathy Keyvani, Niklas Schäfer, Asma Milia, Lale Umutlu, Daniela Pierscianek and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. [European journal of nuclear medicine and molecular imaging · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 3 countries.

Sied Kebir *Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Laurèl Rauschenbach *DKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Manuel WeberDepartment of Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Lazaros LazaridisDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Teresa SchmidtDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Kathy KeyvaniInstitute of Neuropathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Niklas SchäferDivision of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Asma MiliaDepartment of Pulmonology and Cardiology, Petrus Hospital Academic Teaching, Wuppertal, Germany.
Lale UmutluInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Daniela PierscianekDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Martin StuschkeDepartment of Radiotherapy, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Michael ForstingInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Ulrich SureDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Christoph KleinschnitzDepartment of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Gerald AntochDepartment of Diagnostic and Interventional Radiology, University Hospital Düsseldorf, University of Düsseldorf, Düsseldorf, Germany.
Patrick M CollettiDepartment of Radiology, University of Southern California, Los Angeles, USA.
Domenico RubelloDepartment of Nuclear Medicine, Radiology, Neuroradiology, Clinical Pathology, S. Maria Della Misericordia Hospital, Rovigo, Italy.
Ken HerrmannDepartment of Nuclear Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Ulrich HerrlingerDivision of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Björn SchefflerWest German Cancer Center (WTZ), German Cancer Consortium (DKTK), University Hospital Essen, University Duisburg-Essen, Partner Site University Hospital Essen, Essen, Germany.
Ralph A BundschuhDepartment of Nuclear Medicine, University Hospital Bonn, University of Bonn, Bonn, Germany.
Martin Glas *Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. martin.glas@uk-essen.de.ORCID http://orcid.org/0000-0003-3167-3403
University of Duisburg-Essen · DEGerman Cancer Research Center · DEUniversity of Bonn · DEDeutschen Konsortium für Translationale Krebsforschung · DEDüsseldorf University Hospital · DEOspedale Santa Maria della Misericordia di Rovigo · ITUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to test the diagnostic significance of FET-PET imaging combined with machine learning for the differentiation between multiple sclerosis (MS) and glioma II°-IV°.

methodsOur database was screened for patients in whom FET-PET imaging was performed for the diagnostic workup of newly diagnosed lesions evident on MRI and suggestive of glioma. Among those, we identified patients with histologically confirmed glioma II°-IV°, and those who later turned out to have MS. For each group, tumor-to-brain ratio (TBR) derived features of FET were determined. A support vector machine (SVM) based machine learning algorithm was constructed to enhance classification ability, and Receiver Operating Characteristic (ROC) analysis with area under the curve (AUC) metric served to ascertain model performance.

resultsA total of 41 patients met selection criteria, including seven patients with MS and 34 patients with glioma. TBR values were significantly higher in the glioma group (TBRmax glioma vs. MS: p = 0.002; TBRmean glioma vs. MS: p = 0.014). In a subgroup analysis, TBR values significantly differentiated between MS and glioblastoma (TBRmax glioblastoma vs. MS: p = 0.0003, TBRmean glioblastoma vs. MS: p = 0.0003) and between MS and oligodendroglioma (ODG) (TBRmax ODG vs. MS: p = 0.003; TBRmean ODG vs. MS: p = 0.01). The ability to differentiate between MS and glioma II°-IV° increased from 0.79 using standard TBR analysis to 0.94 using a SVM based machine learning algorithm.

conclusionsFET-PET imaging may help differentiate MS from glioma II°-IV° and SVM based machine learning approaches can enhance classification performance.

Indexed as

Machine LearningAdultAgedBrain NeoplasmsFemaleGliomaHumansImage Interpretation, Computer-AssistedMaleMiddle AgedMultiple SclerosisPositron-Emission TomographyRadiopharmaceuticalsTyrosine(18F)fluoroethyltyrosineRadiopharmaceuticalsTyrosineArtificial intelligenceGliomaMultiple sclerosisPETPositron emission tomography

Identifiers

PMID33502678
OpenAlexW3123222455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.